ARWR — ARROWHEAD PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 879407 ·
Last close
$42.99
Market Cap
$6.08B
52W High
$95.49
52W Low
$37.06
ADV30
2,088,755
Next earnings
2027-02-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 37,794,000 | — | -436,627,000 | -428,001,000 | 1,738,257,000 | 62,735,000 | 1,687,753,000 |
| Jun 2026 | 75,253,000 | — | -170,093,000 | -194,280,000 | 2,112,013,000 | 19,685,000 | 1,645,972,000 |
| Mar 2026 | 73,737,000 | — | -141,260,000 | -132,732,000 | 2,268,265,000 | 147,531,000 | 1,669,349,000 |
| Dec 2025 | 264,033,000 | — | 40,809,000 | 30,811,000 | 1,604,181,000 | 71,370,000 | 1,041,484,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-59,055,000
Investing CF
$-801,722,000
Financing CF
$784,187,000
CapEx
$-16,056,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.33
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,923,355,000
Inventory
—
Receivables
$8,556,000
ST Investments
$1,582,275,000
EBIT TTM
$-159,471,000
Pretax Income TTM
$-252,078,000
Interest Exp TTM
$92,607,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$450,816,992
EBITDA
$-680,548,992
Free Cash Flow
$-586,995,392
Enterprise Value
$6,973,346,304
Total Cash
$1,188,782,976
Total Debt
$1,407,374,976
Shares Out
141,368,004
Trailing EPS
$-5.11
Book Value
$0.36
ROE
-258.9%
ROA
-28.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 450,817,000 | -707,171,000 | -724,206,000 | 1,738,257,000 | 1,687,753,000 | 50,313,000 | -271,949,000 |
| Sep 2025 | 829,448,000 | 98,346,000 | -1,631,000 | 1,385,295,000 | 881,879,000 | 466,052,000 | 179,552,000 |
| Sep 2024 | 3,551,000 | -601,080,000 | -599,493,000 | 1,139,802,000 | 948,739,000 | 185,444,000 | -462,851,000 |
| Sep 2023 | 240,735,000 | -205,002,000 | -205,275,000 | 765,552,000 | 478,390,000 | 271,343,000 | -153,890,000 |
| Sep 2022 | 243,231,000 | -178,507,000 | -176,063,000 | 691,939,000 | 273,600,000 | 398,520,000 | -136,131,000 |
TTM Snapshot
Revenues TTM
$669,495,000
NetIncome TTM
$-319,951,000
OpCashFlow TTM
—
Assets (Latest)
$2,112,013,000
Forward EPS
$-2.95
Max Pain — expiry 2026-12-18
max pain strike: $50.00 · spot: $43.11 · call oi: 5,496 · put oi: 1,612Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MIRM | Mirum Pharmaceuticals, Inc. | $6.00B | $91.95 | — |
| LGND | LIGAND PHARMACEUTICALS INC | $5.86B | $293.81 | — |
| BLTE | BELITE BIO, INC | $6.35B | $157.72 | — |
| ORKA | Oruka Therapeutics, Inc. | $6.53B | $96.32 | — |
| GIFLF | Grifols SA | $5.37B | $12.72 | — |
News headlines (Yahoo Finance, 1h cache)
ARWR: Commercial Momentum Builds Ahead of Potential Expansion into sHTG Market
2026-11-18 11:02 · Yahoo
Could RNAi Trial Data Alter The Investment Case For Arrowhead Pharmaceuticals (ARWR)?
2026-11-18 01:10 · Yahoo
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2026-11-17 21:30 · Yahoo
Chardan revisits a top pick in biotech following fiscal 2026 results
2026-11-17 20:46 · Yahoo
Arrowhead Pharmaceuticals, Inc. Q4 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
Arrowhead (ARWR) Q4 2026 Earnings Call Transcript
2026-11-13 05:20 · Yahoo
Arrowhead Pharmaceuticals Q4 Earnings Call Highlights
2026-11-13 02:14 · Yahoo
Arrowhead Pharmaceuticals falls on earnings miss
2026-11-12 22:03 · Yahoo
Arrowhead Research: Fiscal Q4 Earnings Snapshot
2026-11-12 21:22 · Yahoo
Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
2026-11-12 21:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.